1.01
+0.005(+0.50%)
Currency In USD
| Previous Close | 1.01 |
| Open | 1 |
| Day High | 1.06 |
| Day Low | 1 |
| 52-Week High | 1.94 |
| 52-Week Low | 0.66 |
| Volume | 1.54M |
| Average Volume | 1.8M |
| Market Cap | 116.48M |
| PE | -0.76 |
| EPS | -1.33 |
| Moving Average 50 Days | 1.1 |
| Moving Average 200 Days | 1.14 |
| Change | 0 |
If you invested $1000 in Fate Therapeutics, Inc. (FATE) 10 years ago, it would be worth $354.39 as of January 07, 2026 at a share price of $1.01. Whereas If you bought $1000 worth of Fate Therapeutics, Inc. (FATE) shares 5 years ago, it would be worth $8.62 as of January 07, 2026 at a share price of $1.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
GlobeNewswire Inc.
Dec 08, 2025 1:00 PM GMT
FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated First ex-U.S. SLE patient treated with FT81
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 1:00 PM GMT
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
GlobeNewswire Inc.
Oct 26, 2025 3:30 PM GMT
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy Favorable safety p